Self-injected contraceptives: does the investment reflect women’s preferences?

Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across s...

Full description

Bibliographic Details
Published in:BMJ Global Health
Main Authors: Sophia Magalona, Pierre Akilimali, Philip Anglewicz, Peter Gichangi, Elizabeth Omoluabi, Funmilola OlaOlorun, Georges Guiella, Shannon N. Wood, Linnea A. Zimmerman
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Online Access:https://gh.bmj.com/content/7/7/e008862.full
_version_ 1850140184898699264
author Sophia Magalona
Pierre Akilimali
Philip Anglewicz
Peter Gichangi
Elizabeth Omoluabi
Funmilola OlaOlorun
Georges Guiella
Shannon N. Wood
Linnea A. Zimmerman
author_facet Sophia Magalona
Pierre Akilimali
Philip Anglewicz
Peter Gichangi
Elizabeth Omoluabi
Funmilola OlaOlorun
Georges Guiella
Shannon N. Wood
Linnea A. Zimmerman
author_sort Sophia Magalona
collection DOAJ
container_title BMJ Global Health
description Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across sub-Saharan Africa. To date, research on the demand for DMPA-SC as a self-injectable method has been conducted largely with healthcare providers, via qualitative research, or with highly specific subsamples that are not population based. Using three recent rounds of data from Performance Monitoring for Action, we examined population-representative trends in demand, use, and preference for self-injection among current non-users in Burkina Faso, the Democratic Republic of Congo (Kinshasa and Kongo Central regions), Kenya, and Nigeria (Lagos and Kano States). We found that while over 80.0% of women had heard of injectables across settings, few women had heard of self-injection (ranging from 13.0% in Kenya to 24.8% in Burkina Faso). Despite initial increases in DMPA-SC prevalence, DMPA-SC usage began to stagnate or even decrease in all settings in the recent three years (except in Nigeria-Kano). Few (0.0%–16.7%) current DMPA-SC users were self-injecting, and the majority instead were relying on a healthcare provider for administration of DMPA-SC. Among current contraceptive non-users wishing to use an injectable in the future, only 1.5%–11.4% preferred to self-inject. Our results show that self-injection is uncommon, and demand for self-injection is very limited across six settings, calling for further qualitative and quantitative research on women’s views on DMPA-SC and self-injection and, ultimately, their contraceptive preferences and needs.
format Article
id doaj-art-a967dfd1aaec41cba9b5437f6a17a5b7
institution Directory of Open Access Journals
issn 2059-7908
language English
publishDate 2022-07-01
publisher BMJ Publishing Group
record_format Article
spelling doaj-art-a967dfd1aaec41cba9b5437f6a17a5b72025-08-19T23:49:31ZengBMJ Publishing GroupBMJ Global Health2059-79082022-07-017710.1136/bmjgh-2022-008862Self-injected contraceptives: does the investment reflect women’s preferences?Sophia Magalona0Pierre Akilimali1Philip Anglewicz2Peter Gichangi3Elizabeth Omoluabi4Funmilola OlaOlorun5Georges Guiella6Shannon N. Wood7Linnea A. Zimmerman8Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAKinshasa School of Public Health, Kinshasa, Congo (the Democratic Republic of the)Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAInternational Centre for Reproductive Health – Kenya (ICRHK), Mombasa, KenyaDepartment of Statistics and Population Studies, University of the Western Cape, Bellville, South AfricaDepartment of Community Medicine, College of Medicine, University of Ibadan, Ibadan, NigeriaInstitut Supérieur des Sciences de la Population/University of Ouagadougou, Ouagadougou, Burkina FasoDepartment of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USADepartment of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USASubcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across sub-Saharan Africa. To date, research on the demand for DMPA-SC as a self-injectable method has been conducted largely with healthcare providers, via qualitative research, or with highly specific subsamples that are not population based. Using three recent rounds of data from Performance Monitoring for Action, we examined population-representative trends in demand, use, and preference for self-injection among current non-users in Burkina Faso, the Democratic Republic of Congo (Kinshasa and Kongo Central regions), Kenya, and Nigeria (Lagos and Kano States). We found that while over 80.0% of women had heard of injectables across settings, few women had heard of self-injection (ranging from 13.0% in Kenya to 24.8% in Burkina Faso). Despite initial increases in DMPA-SC prevalence, DMPA-SC usage began to stagnate or even decrease in all settings in the recent three years (except in Nigeria-Kano). Few (0.0%–16.7%) current DMPA-SC users were self-injecting, and the majority instead were relying on a healthcare provider for administration of DMPA-SC. Among current contraceptive non-users wishing to use an injectable in the future, only 1.5%–11.4% preferred to self-inject. Our results show that self-injection is uncommon, and demand for self-injection is very limited across six settings, calling for further qualitative and quantitative research on women’s views on DMPA-SC and self-injection and, ultimately, their contraceptive preferences and needs.https://gh.bmj.com/content/7/7/e008862.full
spellingShingle Sophia Magalona
Pierre Akilimali
Philip Anglewicz
Peter Gichangi
Elizabeth Omoluabi
Funmilola OlaOlorun
Georges Guiella
Shannon N. Wood
Linnea A. Zimmerman
Self-injected contraceptives: does the investment reflect women’s preferences?
title Self-injected contraceptives: does the investment reflect women’s preferences?
title_full Self-injected contraceptives: does the investment reflect women’s preferences?
title_fullStr Self-injected contraceptives: does the investment reflect women’s preferences?
title_full_unstemmed Self-injected contraceptives: does the investment reflect women’s preferences?
title_short Self-injected contraceptives: does the investment reflect women’s preferences?
title_sort self injected contraceptives does the investment reflect women s preferences
url https://gh.bmj.com/content/7/7/e008862.full
work_keys_str_mv AT sophiamagalona selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT pierreakilimali selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT philipanglewicz selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT petergichangi selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT elizabethomoluabi selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT funmilolaolaolorun selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT georgesguiella selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT shannonnwood selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT linneaazimmerman selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences